{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:23:03Z","timestamp":1756902183843,"version":"3.44.0"},"reference-count":16,"publisher":"The Pediatric Pharmacy Association","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"abstract":"Persistent methicillin-resistant Staphylococcus aureus<\/jats:italic> (MRSA) bacteremia can be difficult to treat, with growing adult literature supporting the combination of ceftaroline and daptomycin for these patients. Here, we report a pediatric patient with persistent MRSA bacteremia with associated cellulitis, fasciitis, myositis, and a deep venous thrombosis causing septic pulmonary emboli. After being unable to clear the bacteremia on vancomycin and then daptomycin monotherapy, the bacteremia cleared quickly with rapid clinical improvement after the addition of ceftaroline to daptomycin. In support of this case, we also review the adult literature supporting treatment with this combination of antibiotics.<\/jats:p>","DOI":"10.5863\/1551-6776-23.6.490","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T17:04:17Z","timestamp":1547571857000},"page":"490-493","source":"Crossref","is-referenced-by-count":1,"title":["Ceftaroline Plus Daptomycin for Refractory Methicillin- Resistant Staphylococcus aureus Bacteremia in a Child"],"prefix":"10.5863","volume":"23","author":[{"given":"Alan M.","family":"Hall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean M.","family":"McTigue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"10","key":"i1551-6776-23-6-490-b1","series-title":"Antimicrob Agents Chemother","first-page":"5296","article-title":"Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity","volume":"56","year":"2012","unstructured":"Rose\n WE\n , SchulzLT, AndesD, \n et al. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother. 2012;56(10):5296\u20135302."},{"issue":"10","key":"i1551-6776-23-6-490-b2","series-title":"Clin Ther","first-page":"1317","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","year":"2014","unstructured":"Sakoulas\n G\n , MoisePA, CasapaoAM, \n et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther. 2014;36(10):1317\u20131333."},{"issue":"2","key":"i1551-6776-23-6-490-b3","series-title":"Clin Infect Dis","first-page":"158","article-title":"Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding","volume":"53","year":"2011","unstructured":"Dhand\n A\n , BayerAS, PoglianoJ, \n et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011;53(2):158\u2013163."},{"issue":"1","key":"i1551-6776-23-6-490-b4","series-title":"Antimicrob Agents Chemother","first-page":"66","article-title":"Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model","volume":"57","year":"2013","unstructured":"Werth\n BJ\n , SakoulasG, RoseWE, \n et al. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model. Antimicrob Agents Chemother. 2013;57(1):66\u201373."},{"issue":"3","key":"i1551-6776-23-6-490-b5","series-title":"Clin Infect Dis","first-page":"e18","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","year":"2011","unstructured":"Liu\n C\n , BayerA, CosgroveSE, \n et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18\u2013e55."},{"issue":"12","key":"i1551-6776-23-6-490-b6","series-title":"Antimicrob Agents Chemother","first-page":"6192","article-title":"Beta-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives","volume":"56","year":"2012","unstructured":"Mehta\n S\n , SinghC, PlataKB, \n et al. Beta-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother. 2012;56(12):6192\u20136200."},{"issue":"4","key":"i1551-6776-23-6-490-b7","series-title":"Pharmacotherapy","first-page":"375","article-title":"Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens","volume":"30","year":"2010","unstructured":"Steed\n ME\n , RybakMJ.\n Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Pharmacotherapy. 2010;30(4):375\u2013389."},{"issue":"5","key":"i1551-6776-23-6-490-b8","series-title":"Pediatr Infect Dis J","first-page":"486","article-title":"Ceftaroline activity tested against bacterial isolates causing community-acquired respiratory tract infections and skin and skin structure infections in pediatric patients from United States hospitals: 2012\u20132014","volume":"36","year":"2017","unstructured":"Pfaller\n MA\n , MendesRE, CastanheiraM, \n et al. Ceftaroline activity tested against bacterial isolates causing community-acquired respiratory tract infections and skin and skin structure infections in pediatric patients from United States hospitals: 2012\u20132014. Pediatr Infect Dis J. 2017;36(5):486\u2013491."},{"issue":"8","key":"i1551-6776-23-6-490-b9","series-title":"Pediatr Infect Dis J","first-page":"837","article-title":"Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011\u20132012)","volume":"33","year":"2014","unstructured":"Sader\n HS\n , MendesRE, FarrellDJ, \n et al. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011\u20132012). Pediatr Infect Dis J. 2014;33(8):837\u2013842."},{"series-title":"Teflaro (ceftaroline fosamil) [prescribing information]. Revised 2016","key":"i1551-6776-23-6-490-b10","unstructured":"Teflaro (ceftaroline fosamil) [prescribing information]. Revised 2016. St Louis, MO: Forest Pharmaceuticals Inc."},{"issue":"5","key":"i1551-6776-23-6-490-b11","series-title":"J Antimicrob Chemother","first-page":"1267","article-title":"Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy","volume":"67","year":"2012","unstructured":"Ho\n TT\n , CadenaJ, ChildsLM, \n et al. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012;67(5):1267\u20131270."},{"issue":"6","key":"i1551-6776-23-6-490-b12","series-title":"Int J Antimicrob Agents","first-page":"557","article-title":"Use of ceftaroline after glycopeptide failure to eradicate methicillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations","volume":"44","year":"2014","unstructured":"Paladino\n JA\n , JacobsDM, ShieldsRK, \n et al. Use of ceftaroline after glycopeptide failure to eradicate methicillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations. Int J Antimicrob Agents. 2014;44(6):557\u2013563."},{"series-title":"Cubicin (daptomycin) [prescribing information]. Revised 2017","key":"i1551-6776-23-6-490-b13","unstructured":"Cubicin (daptomycin) [prescribing information]. Revised 2017. Whitehouse Station, NJ: Merck Sharp & Dohme Corp."},{"issue":"12","key":"i1551-6776-23-6-490-b14","series-title":"Pediatr Infect Dis J","first-page":"1128","article-title":"Daptomycin therapy for invasive gram-positive bacterial infections in children","volume":"26","year":"2007","unstructured":"Ardura\n MI\n , Mej\u00edasA, KatzKS, \n et al. Daptomycin therapy for invasive gram-positive bacterial infections in children. Pediatr Infect Dis J. 2007;26(12):1128\u20131132."},{"issue":"9","key":"i1551-6776-23-6-490-b15","series-title":"Pediatr Infect Dis J","first-page":"893","article-title":"Randomized multicenter study comparing safety and efficacy of daptomycin versus standard of care in pediatric patients with staphylococcal bacteremia","volume":"37","year":"2018","unstructured":"Arrieta\n AC\n , BradleyJS, PopejoyMW, \n et al. Randomized multicenter study comparing safety and efficacy of daptomycin versus standard of care in pediatric patients with staphylococcal bacteremia. Pediatr Infect Dis J. 2018;37(9):893\u2013890."},{"issue":"6","key":"i1551-6776-23-6-490-b16","series-title":"Antimicrob Agents Chemother","first-page":"3177","article-title":"Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic\/pharmacodynamic model of simulated endocardial vegetations","volume":"58","year":"2014","unstructured":"Werth\n BJ\n , BarberKE, IrelandCE, RybakMJ.\n Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic\/pharmacodynamic model of simulated endocardial vegetations. Antimicrob Agents Chemother. 2014;58(6):3177\u20133181."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/23\/6\/article-p490.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/23\/6\/490\/1785199\/1551-6776-23_6_490.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/23\/6\/article-p490.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/23\/6\/article-p490.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:36:22Z","timestamp":1747355782000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/23\/6\/article-p490.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":16,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-23.6.490","relation":{},"ISSN":["1551-6776"],"issn-type":[{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2018]]}}}